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1. Introduction 
Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease  characterized by 
the production of numerous autoantibodies that typically involves multiple organ systems. 
As opposed to lupus in animal models, SLE in humans is heterogeneous and affects 
different individuals with a wide range of disease courses and manifestations. The 
pathogenesis is still unclear, a myriad of innate and adaptative immune system aberrations 
in SLE have been identified as major contributors of the disease. 
Cytokines are a diverse group of soluble proteins and peptides, produced and released by 
immune system cells , that act as humoral regulators and modulate the functional activities 
of individual cells and tissues, playing a pivotal role in the differentiation, maturation, and 
activation of various immune and no immune cells. Cytokine dysregulation is likely to play 
a role in the loss of immune tolerance that leads to SLE, and in the damage resulting from 
the disease. Many of the genes that are associated with risk for lupus are cytokines, 
regulators of cytokines, or downstream members of cytokine pathways. 
Multiple cytokines have been implicated in the disease activity or organ involvement in 
SLE. Among these, IL-6, Interferon (IFN), B-lymphocyte stimulator (BlyS), IL-10, IL-17 is 
thought to play an important role in the creation of the characteristic milieu in SLE,  which 
promotes B-cell survival and autoantibody production. On the other hand, also cytokines 
like IL-10, IL1, TNF-ǂ , IFN,  are important in development of the autoimmune injury in 
renal and central nervous system, the most frequently observed causes of death in patients 
with SLE. Moreover, recent studies strongly suggest  that the cytokines, at least in part, 
would be implicated in the pathogenesis of accelerated atherosclerosis associated with SLE.  
The  knowledge of cytokines not only provides new insight into pathogenesis of SLE, but 
also it has allowed the development of clinical applications such as monitoring of disease 
and as potential therapeutic targets with the use  of several biologic agents, targeting 
different cytokines or their receptors. Consequently, many trials of anticytokine therapies 
for SLE are underway.  
The focus of the present chapter is to summarize the cytokines which have significant 
implications in the pathogenesis of SLE, the potential clinical and therapeutic use will be 
reviewed.  
2. SLE gender susceptibility and cytokines 
One feature of lupus, which also occurs with other autoimmune diseases, is the influence of 
gender on disease susceptibility. In fact 90% of people affected by lupus are women (Masi & 
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Kaslow 1978). Immunological, epidemiological and clinical evidence suggest that female sex 
hormones play an important role in the etiology and pathophysiology of chronic immune 
diseases.  Abundant studies have suggested that gender differences in susceptibility to SLE 
are mediated by sex hormones (Rider & Abdou 2001, Cohen-Solal et al  2006, Zandman et al 
2007) .The  high female prevalence is most marked after puberty: while the pre-puberty 
female to male ratio is 3 : 1, this increases to 10 : 1 during the childbearing years and 
decreases again to 8 : 1 after menopause (Lahita et al 1999a). Pregnancy is frequently 
associated with activity and flares of the disease in SLE patients (Lahita 1999a). Also there is 
an increased risk of developing SLE in postmenopausal women who received estrogen 
hormone replacement therapy (Buyon et al 2007) and increased the risk  of flares in 
postmenopausal patients (Straub 2007). Together these considerations indicate that estrogen 
may be proposed as candidates to explain the sexual dimorphism of SLE. Cytokines are 
intimately involved with sex hormones, as they regulate the level of sex hormones both 
systemically and locally, especially in the reproductive organs. The interactions between 
cytokines and estrogens affect important cellular activities as proliferation and apoptosis 
(Lahita  1999b).  
Estrogens exert their effects by activation of intracellular receptors,  the estrogen receptor 
alpha (ERǂ) and beta (ERǃ) (Green et al 1986). In addition to its intracellular receptors have 
also been reported  membrane receptors that correspond to full-length isoforms of both ERǂ 
and  ERǃ with extracellular functionality (Pedram et al 2006). Both receptors have been 
identified in the membrane of thymocytes and have a great importance in the proper 
development of the thymus (Stimson & Hunter 1980). Thus it seems that estrogen receptors 
influence the adequate development of T lymphocytes. It is well known that low doses of 
estrogen promote enhanced Th1 responses and increased cell-mediated immunity, while 
high doses of estrogen lead instead to increased Th2 responses and antibodies production 
(Maret et al 2003, Bao et al 2002). This effect of estrogens seems to be achieved through 
direct alteration in the Th cytokine profile from a proinflammatory (IL-2, IFN-γ) to an 
humoral direction ( IL-4, IL-5, IL-9, IL-13).  Besides the effect of estrogen on the profile of 
cytokines released by T cells, estrogen also increases the release of IL-1, IL-6 and TNF by 
monocytes/macrophages (Kramer et al 2004). SLE patients  show immune-related  disorders 
mediated through estrogens. In vitro peripheral blood mononuclear cells in SLE patients 
show an increase in anti-dsDNA and IL-10 in response to estrogen, and in vivo there are 
clear differences in hormonal and cytokine levels in SLE vs control pregnancies (Doria et al 
2004). Although there is much indirect evidence for estrogen involvement in the lupus 
disease process, the direct role of estrogen/estrogen-receptor mediated pathways in 
regulating cytokine production in SLE patients has not as yet been clearly defined. The first 
evidence for a molecular marker of estrogen action in SLE was the estrogen dependent 
changes  in lupus T-cells calcineurin that could alter  cytokine regulation (Rider et al 1998). 
Calcineurin is the target of a class of drugs called calcineurin inhibitors, which includes 
cyclosporine, pimecrolimus and tacrolimus. Calcineurin induces different transcription 
factors as NFATs that are important in the transcription of cytokine genes. A recent study 
demonstrate that blocking estrogens receptor in vivo in SLE pre- menopausal women they 
reduced the expression of calcineurin in peripheral T cells (Abdou et al  2008). Another 
possible mechanism of the role of estrogen in gender susceptibility in lupus is the altered 
expression of its receptors. Peripheral cells of SLE patients showed increased expression of 
ERǂ  mRNA and decreased expression of ERǃ (Iinui et al 2007).  ERs are  overexpressed in 
CD4+ and CD8+ cells while  is decreased in B cells. The decline in ERǃ  expression inversely 
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correlated with SLEDAI score. In conclusion, estrogen and its ability to influence on the  
profiles of cytokines release and immune system regulation is a very powerful  factor in the 
gender susceptibility described in lupus.  
3. Cytokines involved in SLE 
3.1 Th1/Th2 balance in SLE 
The Th1/Th2 balance hypothesis emerge from observations in mice of two subtypes of CD4 
T-helper cells differing in cytokine secretion patterns and other functions (Mosmann et al 
1986). The concept subsequently was applied to human immunity (Mosmann et al 1989). 
Th1 cells release significantly INFǄ and IL2, and through these mediators Th1- polarized 
responses are highly protective against infections  especially the intracellular pathogens, 
because of the ability of Th1-type cytokines to activate phagocytes and enhance the cellular 
response.  In contrast Th2 cells release mainly IL4, IL5  IL9 and IL13 and induce  the in situ 
survival of eosinophils (through IL-5), promote the production by B lymphocytes of high 
amounts of antibodies, including IgE (through IL-4 and IL-13), as well as the growth and 
degranulation of mast cells and basophiles (through IL-4 and IL- 9). (figure 1)  
 
 
Fig. 1. Diagrammatic representation of the differentiation into Th1 or Th2 cells from  
naive cells.  
Antigen-presenting cells interact with undifferentiated cells secreting specific cytokines that 
induce differentiation toward Th1 or Th2 cells. INFǄ released by Th1 cells and IL4 produced 
by Th2 cells act as their own growth factors and cross-regulate  the other   differentiation. 
Two features define the Th1/Th2 balance, first each cell subset produced cytokines  that 
served as their own growth factor (autocrine effect) and second the two subsets released 
cytokines to cross regulate each other's development. Polarization to a subtype or another 
depends largely on the APC and experience on the antigen. This process is directed by the 
microenvironment of cytokines resulting in the antigen presentation of APC to T naive cells. 
A Th1/Th2 imbalance with excess of Th1 predominance appears in organ specific 
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inflammatory diseases as arthritis, multiple sclerosis and type 1 diabetes,  and  instead a 
predominance of Th2 response has been described in allergy and systemic autoimmune 
diseases (Abbas et al  1996).   
The roles of Th1 and Th2 cytokines in the pathogenesis of SLE are controversial. In patients 
with SLE, Th2 cytokines are increased (Ogawa et al 1992), whereas Th1 cytokines are 
decreased (Klinman & Steinberg 1995 ). Thus, SLE was initially considered to be a Th2 
predominant disease. However different results contradict this hypothesis like that IFNγ 
levels in the sera of patients with SLE are significantly elevated and that there is a 
correlation between the severity of SLE and the amount of IFNγ secreted  (Al-Janadi et al 
1993). All these findings suggest that the Th1 and Th2 responses are both important in the 
pathogenesis of lupus associated tissue injury. SLE is a disease involving a wide spectrum of 
cytokines. SLE patients with arthritis have higher IFNγ  levels than  the other patients, and 
conversely, patients with serositis or CNS involvement have higher IL-4 levels (Chang et al 
2002). Furthermore SLE patients with nephritis have higher Th1 cytokines in serum and 
urine than non-nephritis patients (Chang et al 2006). Still more  a significant difference in the 
Th1/Th2 balance in peripheral blood exists between WHO class IV and V lupus nephritis.  
Th1 cells are predominant in class IV but not in class V (Akahoshi et al 1999). In class V, the 
number of infiltrating cells was reduced, with a large percentage of CD4 T cells producing 
IL4 in the peripheral blood (Masutani et al 2001).  
SLE is known to be a heterogeneous disease in which a wide range of cytokines are 
involved, it seems the most likely that Th1 or Th2 dominance depends on the stage of the 
disease and involvement. The Th2 response would be related to the development and 
production of autoantibodies, and Th1 with immune-mediated inflammatory activity.  
3.2 B-lymphocytic Stimulator (BLyS) 
BlyS a member of theTNF family, is also known as the B cell–activating factor(BAFF) and 
appears to play an important role in the differentiation  and survival of B cells (Mackay et al  
2002).  BlyS can be released in a soluble form or can be expressed as a transmembrane 
protein on a wide variety of cell types, including monocytes, activated neutrophils, T cells, 
and DCs and its release is upregulated by IFN-Ǆ, IL-10, G-CSF and CD40L (Nardelli et al  
2001, Moore et al 1999,  Litinskiy et al 2002, Harigay et al 2008). 
BLyS binds to 3 receptors, BAFF-R (BAFF receptor), TACI (transmembrane activator and 
calcium modulator and cyclophylin ligand anteractor), and BCMA (B-cell maturation 
antigen), that are differentially expressed during B cell ontogeny (Bossen  & Schneider 2006, 
Bossen et al 2008). The stimulation of all three receptors promotes B-cell differentiation and 
proliferation. BLyS is the sole ligand for BAFF-R, whereas TACI and BCMA each can bind 
either BLyS or another TNF family ligand known as a proliferation-inducing ligand (APRIL) 
(Bossen et al 2008).  
After maturation in the bone marrow, newly formed B cells migrate to the secondary 
lymphoid organs (spleen and lymph nodes). These B cells do not possess all the 
characteristics of fully mature B cells, and they are referred to as transitional B cells. This 
transitional stage is an elastic checkpoint where thresholds for negative selection are 
homeostatically adjusted by free BLyS concentration.  At this point an upregulation of  BLyS 
expression can result in the rescue of self-reactive B cells from elimination. This effect 
explains, at least in part, the greatly increased levels of autoantibody production and 
associated autoimmune manifestations observed in transgenic mice that overexpress BlyS 
(Cancro et al  2009, MacKay et al 2007, Zheng et al  2005,  Miller et al 2006, Thien et al 2004) 
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Elevated BLyS serum levels are often observed in SLE patients and correlate with disease 
activity (Petri et al 2008). Experiments in mice, have been  demonstrated causality between 
BLyS over expression and development of SLE , on the other hand, also had been  
documented the amelioration of clinical disease in SLE mice following  treatment with  BlyS 
antagonist (Mackay et al 1999, Petri et al 2008, Jacob et al 2006) 
The primary source of BlyS secretion in SLE remains speculative, a secretion by DCs 
(dendritic cells), a profoundly dysregulated IFNs in SLE  or an increased levels of BLyS 
resulting from the presentation of self antigens (derived of an defective clearance of 
apoptotic bodies) to innate immune cells (which express BLyS upon antigenic stimulation) 
are potentially mechanisms implicated (Cancro et al 2009).  
Because BLyS may figure prominently in the development of SLE and it  could be a valid 
target for SLE, therapy with BLyS antagonists have been developed.  Belimumab, a fully 
human monoclonal Ab (IgG1) that binds soluble BLyS and inhibits its binding to TACI, 
BCMA, and BR3, and  Atacicept (TACI-Ig)  a soluble, recombinant fusion protein of the 
human IgG1 Fc and the extracellular domain of the TACI receptor that binds BLyS and 
APRIL, have been tested in clinical trials. Results from phase III trials have demonstrated 
the safety profile and efficacy of belimumab in controlling SLE in a broad range of patients 
(Navarra et al 2011).  
3.3 Interferon-α 
Interferon alpha (INF-ǂ) is  produced mainly by  plasmocytoid dendritic cells (PDC) in 
response to viral infection. INF-ǂ is not one protein, but rather a family of highly related 
proteins encoded on the short arm of chromosome 9,  and  called type I INFs. Studies in 
which cellular mRNAs are screened against thousands of gene sequences have 
demonstrated that in SLE patients the INF-ǂ induced genes are the most overexpresed  of all 
those assayed (Baechler et al 2003). Evidence of the effect of INF-ǂ in SLE comes from 
observations on the therapeutic administration of IFN-ǂ in various types of malignancies  
and hepatitis C infection. Case reports emerged describing the development of lupus 
associated autoantibodies and even clinical lupus (Niewold & Swedler 2005).  
Discontinuation of IFN-α typically resulted in remission of SLE symptoms, supporting a 
causal relationship with IFN-α. Only a minority of patients treated with IFN-α develop  
SLE (<1% of patients) , these data support the idea that IFN-α can be sufficient to induce  
SLE in some genetically designed individuals. In addition,  SLE patients commonly harbor 
anti INF-ǂ  autoantibodies. Anti INF-ǂ antibodies-positive patients have lower levels of 
serum type I IFN bioactivity and evidence for reduced downstream IFN-pathway and 
disease activity. 
A very strong correlation is consistently observed between the presence of SLE-associated 
autoantibodies that recognize nucleic acid structures or RNA-containing protein, such as 
anti-Ro, anti-La, anti-Sm, anti-RNP, and anti-dsDNA and high production of INF-ǂ (Kirou 
et al 2005). Also lupus patients with high serum IFNα had a significantly higher prevalence 
of cutaneous and renal disease in most studies (Dall'era  et al 2005). It is interesting that both 
of these clinical manifestations share an association with a particular serology (rash with 
anti-Ro and nephritis with anti-dsDNA).  
The principal mechanism through which INF-ǂ is produced in SLE is through Toll-like 
receptors (TLR). TLR receptors is a family of receptors present in a variety of cells and that 
recognize characteristics ligand present in pathogens. Some TLR recognize RNA and DNA 
sequences of single or double chain. A quality of many cases of lupus is the production of 
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autoantibodies against RNA or DNA containing protein complexes such as Sm, RNP, Ro, 
and La. Autoantibodies specific for these lupus-associated riboproteins can bind with 
antigens derived from apoptotic cells. The RNA/DNA found in these complexes are capable 
of promoting the production of IFN-α through the stimulation of TLR. Because some TLR is 
located in the endosomes, RNA  or DNA containing complexes must access the interior of 
the cell before they are able to act as activators. The Fc portions of the immune complexes 
are recognized and internalized by cells with Fc receptors in their surface, providing a route 
of entry for RNA or DNA  to reach TLR, resulting in interferon alpha production (Figure 2). 
This process is especially well established in PDCs  on TLR7 and  TLR9 (Båve et al 2003).  
 
 
Fig. 2. Induction of INF-ǂ in lupus. RNA/DNA containing immunecomplexes access  the 
interior of the cell through recognition of Fc portion by Fc receptors in PDC membrane. 
Inside cell the RNA/DNA  specific ligand are recognized by Toll-like receptors (TLR).   
TLR depending signals reach to the cell nucleus and induces transcription of IFN genes. 
INF-ǂ generate an effective antigen-presenting cells state by mediating maturation of  
dendritic cells. Thus INF-ǂ  prime the immune system for augmented sensitivity to 
subsequent stimuli. The activate antigen presenting cell state may also be characterized by 
an augmented capacity to generate a peripheral T-cell repertoire enriched in autoreactive 
cells. Dendritic cells  are primary activators of T-cells and affect both tolerance and 
activation, depending of the  state of dendritic cells. Dendritic cells from lupus patients  are 
able to present self-antigens to T-cells in  a stimulatory rather than regulatory manner, a 
process which is INF-ǂ dependent (Blanco et al 2001). Moreover PDCs significantly enhance 
autoreactive B cell proliferation, autoantibody production, and survival in response to TLR 
activation (Ding et al 2009). Recently it has been reported that activation of the IFN signaling 
pathway may be linked to the risk of atherosclerosis by affecting plaque formation in 
patients with SLE (Li et al 2011). 
In conclusion, in SLE patients, some autoantibodies are able to induce the production of 
INF-ǂ. INF-ǂ enhances the  autoimmunity and immune response.  
3.4 Tumor necrosis factor-α (TNF-α) 
TNF-ǂ is a pleiotropic cytokine produced by a variety of cell types including monocytes, 
lymphocytes and non immunological cell types in response to inflammation, infection and 
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other environmental challenges. There are controversial results about the role of TNF in 
mice lupus strains. In NZB/W stain diminished production of TNF-ǂ has been reported 
demonstrating the protective effect of TNF-ǂ (Jacob  & McDevitt 1988). In other strains of 
murine lupus an increased production of TNF-ǂ has been described.  In addition, TNF-ǂ 
concentration correlates with the severity of the illness and anti-TNF therapy is profitable 
(Boswell et al 1988). Overall, these results show a duality in the role of TNF in lupus, one 
beneficial and one detrimental.  
TNF-ǂ contributes to avoiding the development of autoimmunity and autoantibody 
production. When introducing inhibitory TNF-ǂ therapies in patients with diseases such as 
arthritis, spondyloarthropathies or Crohn disease shows the appearance of antinuclear 
antibodies and anti-ds DNA antibodies (De Ricke et al 2003, Garcia-Planella et al 2003). 
Normally these antibodies are not pathological, but in a few patients autoantibodies are 
associated with a SLE-like activity. TNF-ǂ blocker induced lupus is usually benign and the 
symptoms resolve after TNF blockade stopped (Ramos-Casal et al 2007). It should be noted 
that these patients do not have the genetic background that makes them susceptible to SLE 
developing. When using anti-TNF therapy in SLE patients it has been found an elevation of 
antinuclear and anticardiolipin antibodies in most patients (Aringer et al 2007). This 
elevation was transient and did not produce complement consumption or lupus flare. 
On the other hand numerous studies have shown that TNF blockade in SLE patients 
suffering from arthritis, nephritis and skin lesions were clinically effective in open clinic 
trials (Aringer et al 2004, Hayat el al 2007). It has found expression of TNF-ǂ in inflamed 
tissue biopsies in patients with lupus, which does not occur in healthy individuals (Herrera-
Esparza et al 1998), and TNF-ǂ expression is associated with high histological disease 
activity (Zha et al 2009).  
TNF-ǂ performs two major functions: one as an immunoregulatory cytokine and the other 
as a potent mediator of inflammation. Among the immunoregulatory functions TNF-ǂ 
induces the release of antiapoptotic molecules, TNF blockade may lead to increased 
apoptosis (Aringer et al 2007). The resulting increase in apoptotic material could explain 
why the emerging antibodies appear to exclusively target nuclear antigens and 
phospholipids, both of which are expressed on apoptotic bodies (Utz et al 1997). In addition, 
TNF blockade hampers the elimination of autoimmune B lymphocytes by cytotoxic T cells 
(Via et al 2001). All together could explain the pathways to increased lupus autoantibodies 
under TNF-ǂ blockade.  
The immunecomplexes generated by autoantibodies are deposited in tissues and organs. 
The deposit of immunecomplexes mediated inflammatory process triggered largely by  
TNF-ǂ. The expression of TNF-ǂ activates the local inflammation and tissue damage. TNF-α 
is the most important proinflammatory cytokine and a harbinger of tissue destruction, and it 
is at the top of a pro-inflammatory “cascade” leading to tissue damage. In contrast to the 
complex role of TNF-α in apoptosis and in immune regulation, its powerful 
proinflammatory effects are unequivocal. At the tissue level, TNF blockade induces 
remission of inflammation and hence tissue recovery. Anyway in the use of anti-TNF 
therapy is important to note the dual activity of this cytokine. 
3.5 IL-6 
IL6 is a pleiotropic cytokine, structurally, it shares homology with other cytokines: 
oncostatin M, IL11, leukaemia inhibitory factor, ciliary neurotrophic factor and 
cardiotrophin (Hirano, 1998). It was known initially as B-cell stimulatory factor 2 because it 
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stimulates B cell growth and maturation to antibody-producing plasma cells. It is produced 
by a wide range of cell types including, monocytes, T cells, fibroblasts, synoviocytes and 
endothelial cells. IL-6 beyond his capacity of B cell activation and promotion of  
Ig production, play an important role in governing inflammation process (Ishihara et al., 
2002).   
IL-6 responses are transmitted through gp130, which serves as the universal signal-
transducing receptor subunit for all IL-6-related cytokines. Although this classically occurs 
through IL-6 binding to its membrane-bound receptor (IL-6R), it is clear that a soluble form 
of the cognate IL-6 receptor (sIL-6R) affords IL-6 with an alternative mechanism of gp130 
activation. This additional mode of cell activation is termed IL-6 trans-signaling and results 
from formation of a sIL-6R_IL-6 complex, which can directly bind cellular gp130. Because 
gp130 is ubiquitously expressed within tissue, trans-signaling provides IL-6 with the 
capacity to activate cells that would not intrinsically respond to IL-6 itself (Hibi et al., 1990; 
Hirano et al., 1994; McLoughlin  et al., 2005). Therefore, IL-6 and gp130 signaling plays a 
critical role in the inflammatory process and tissue injury (Nechemia-Arbely et al., 2008). 
An association between IL-6 and progression of lupus has been published for several 
murine models of SLE. The direct role of IL-6 in controlling autoantibody production has 
been demonstrated  in the pristane induced model of lupus (Richards  et al., 1998). On the 
other hand the administration of recombinant IL-6 to female NZB/W mice exacerbates the 
progression of glomerulonephritis (Ryffel  et al., 1994). Anti IL-6 monoclonal antibody given 
in MRL lpr lupus prone mice, has been shown to cause a decrease in renal damage and a 
temporary reduction in levels of anti-dsDNA antibody production (Kiberd  1993).  
Elevated levels of IL-6 have been found in the serum and in the urine of active SLE patients 
(Chun  et al., 2007; Grondal  et al., 2000; Horii  et al., 1993). Raised expression of gp130, has 
been found in patients with active SLE, while an important reduction in the gp130 
expression on B lymphocytes was observed when the activity of the disease had 
disappeared after readjusting its  immunosuppressive treatment (De La Torre et al., 2009). 
Therefore, monitoring the frequency of gp130, could provide a useful tool in the diagnosis 
and monitoring of disease activity in patients with lupus. 
Beyond  the ability of IL-6 to stimulate B-lymphocyte differentiation into immunoglobulin 
secreting cells, IL-6  in concert with TGF-B  is a critical cofactor for Th17 development, 
whereas the absence of IL-6  induces Foxp3, thereby specifying Treg development (Weaver 
et al., 2006). The two T-cell subsets play prominent roles in immune functions: Th17 cell is  
a key player in the pathogenesis of autoimmune diseases and protection against bacterial 
infections, while Treg functions to restrain excessive effector T-cell responses (Kimura et  
al., 2010). 
Factors leading to the constitutive expression of IL-6 in SLE have not been elucidated yet, 
they may involve other regulator cytokines, like IL-10, or may be due, at least in part, to 
genetic differences (Linker et al., 1999; Tackey  et al., 2004). 
Recently, tocilizumab, a humanized monoclonal antibody against the ǂ-chain of the IL-6 
receptor, which prevents the binding of IL-6 to membrane bound and soluble IL-6 receptor, 
has been tested in SLE patients, with promising results (Illei  et al., 2010). 
3.6 IL-2  
The cytokine IL-2 is a multifactorial cytokine. It was initially identified as a potent T cell 
growth factor, however, more recent data strongly indicate that IL-2 is essential for immune 
tolerance (Humrich  et al., 2010). IL-2 constitutes a key element in the maintenance of the 
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homeostasis between a proliferative immune response and the induction of tolerance, which 
supports the involvement of this cytokine in diverse autoimmunity disorders, such as SLE  
(Sharma  et al., 2011). Predominantly produced by activated CD4+ and CD8+ T cells, IL-2 
exerts its functions trough the interaction with its receptor (IL-2R) (Kammer, 2005).  
It has been reported that production of IL-2 is decreased in patients with SLE (Sharma  et al., 
2011). Transcriptional regulators responsible for the transcription or suppression of IL-2 
production are imbalanced in SLE T cells and this explains the reduced IL-2 levels found in 
SLE patients (Solomou  et al., 2001). The decreased production of IL-2 in SLE patients most 
likely contributes to various immune defects such as decreased Treg production, decreased 
activation-induced cell death (AICD), and potentially decreased cytotoxic T lymphocytes 
(Lieberman & Tsokos 2010). 
 IL-2 signals are critical for the outcome of a CD8+ T cell response.  Recently it was 
discovered that a strong IL-2 signal promotes the progressive acquisition of effector T cell 
functions (such as perforin and granzyme B expression, the hallmarks of CD8+ T cell 
cytotoxicity) but decreases the capacity to generate cells with memory features. By contrast, 
in conditions of weak IL-2 signaling, T cells fail to acquire the full program of effectors 
differentiation.( Pipkin et al., 2010) 
IL-2 module activation-induced cell death (AICD). The activation of AICD is a mechanism 
of self tolerance in which apoptosis of autoreactive lymphocytes is induced after repeated 
stimulation. The deficiency in activation induced cell death might be related to the 
persistence of autoreactive T cell clones that eventually may lead to the activation of B cell 
subsets, with the subsequent production of autoantibodies and the development of 
autoimmune disorders (Gómez-Martín  et al., 2009).  
IL-2  is also required for the expansion and conversion of CD4+foxp3-T cells into CD4+ 
foxp3+ cells or regulatory T cells (Treg) (Setoguchi  et al., 2005; Zheng  et al., 2007;). Tregs 
cells, are necessary for maintaining tolerance to self antigens and they are able to do is by 
suppressing self-reactive T cells (Buckner , 2010). It has been well recognized that a decline 
in Tregs as a critical event in the development of systemic autoimmunity both mice and SLE 
patients (Valencia et al., 2007; Suzuki et al., 1995). On the other hand, recently IL-2 signaling 
has been shown to play a role in inhibiting the development of Th17 cells (Tato et al., 2007; 
Ma et al., 2010). Thus, the effects of IL-2 on Treg and Th17 cells may serve to promote auto-
reactivity while at the same time inhibiting a counter regulatory response (discussed later). 
3.7 IL-17 
Interleukin 17 (IL-17) is a proinflammatory cytokine that is involved in defending the host 
against extracellular, some intracellular pathogens and fungi (Bettelli et al., 2008; Khader  
et al., 2010). IL-17 promote inflammation on several levels, as their receptors are expressed 
on both hematopoietic cells and non hematopoietic cells. Il-17 exerts its effects through  
the recruitment of monocytes and neutrophils by increasing the local production of 
chemokines. IL-17 can also stimulate B-cell antibody production (Hsu et al., 2008; 
Mitsdoerffer et al., 2010). 
Recent studies have reported that production of IL-17 is abnormally high in patients with 
SLE. Its levels are increased in SLE sera and correlate with SLE disease activity. Moreover, 
the frequency of IL-17-producing T cells is increased in the peripheral blood of patients with 
SLE (Crispín  & Toscos, 2010; Shah et al., 2010).  Recent evidence indicates that a significant 
fraction of the IL-17 produced in SLE derives from Th17 cells and CD3+CD4-CD8- (double 
negative or DN) T cells (Nalbandian  et al., 2009).  
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The identification of Th17-lineage-specific transcription factors, established Th17 cells as an 
independent T-cell subset. Differentiation of naïve T cells into Th17 cells depends on TGF-ǃ 
and IL-6, being IL-23 essential for expansion and maintenance of pathogenic Th17 cells 
(Jäger & Kuchroo, 2010). Interestingly, the participation of TGF-ǃ in the differentiation of 
Th17 cells places the Th17 lineage in close relationship with CD4+CD25+Foxp3+ regulatory T 
cells (Tregs), as TGF-ǃ also induces differentiation of naive T cells into Foxp3+ Tregs in the 
peripheral immune compartment (Korn  et al., 2009).  
In light of this knowledge, now is the general notion that there is a reciprocal relationship 
between pro-inflammatory IL-17-producing Th17 cells and protective Foxp3+ Tregs. The 
presence of pro-inflammatory cytokines like IL-6, which is induced during infection, 
inflammation or injury, inhibited the induction of Foxp3+ Tregs and simultaneously 
promoted Th17-cell differentiation (Bettelli et al., 2006). On the other hand, tolerance 
induction was associated with decreased IL-6 production and increased TGF-ǃ production 
that paralleled a reduction in the fraction of IL-17-producing T cells and a reciprocal 
increase in regulatory T cells (Kang  et al., 2007). Therefore, some authors support the notion 
that therapeutic intervention in SLE should focus on therapeutic agents that can regulate the 
immune balance between Th17 and Treg cells rather than on those that exclusively regulate 
Th17 cells or a specific cytokine (Yang et al., 2011). 
3.8 IL-10 
Interleukin (IL)-10 is one of the most important cytokine with anti-inflammatory properties. 
Today it its known that the ability to synthesize IL-10 is not limited to certain T cells subsets, 
but is characteristic of almost all leukocytes. Very important sources in vivo appear to be 
mainly monocytes and macrophages as well as Th cells (Sabat et al., 2010). 
IL-10 is a potent inhibitor of antigen presentation. The other profound effect of IL-10 is to 
inhibit the production of proinflammatory cytokines and mediators from macrophages and 
DCs. The major inflammatory cytokines, IL-1, IL-6, IL-12, and tumor necrosis factor (TNF), 
are all dramatically repressed following exposure to IL-10. On the other hand, IL-10 can 
costimulate B-cell activation, prolong B-cell survival, and contribute to class switching in B 
cells (Mosser & Zhang, 2008). 
Multiple studies have reported high levels of IL-10 in SLE patients and in murine models of 
lupus, and this increase correlated with disease activity (Capper et al., 2004; Hagiwara et al., 
1996; Houssiau et al., 1995; Park et al., 1998). However, the specificity of these findings is 
unclear. A recent study  that investigated the role of IL-10 in a novel congenic model of 
lupus, B6.Sle1.Sle2.Sle3 (B6.TC) showed, that  although B6.TC mice produced higher IL-10 
levels that nonautoimmune control mice, an overexpression of IL-10 decreased T-cell 
activation, auto-antibody production and autoimmune pathogenesis (Blenman et al., 2006).  
Interestingly, other study has recently been shown that the presence of immune complexes  
and IFNǂ a cytokine implicated in the pathogenesis of SLE, decreases the capacity of IL-10 
to suppress inflammation, limiting therefore the anti-inflammatory effect of this cytokine 
(Yuan et al., 2011). These results reinforce the notion that IL-10 exerts multiple functions and 
we must be cautious in equating high levels of IL-10 and increased pathogenesis in systemic 
autoimmunity (Blenman et al., 2006).  
4. Cytokines in organ damage  
4.1 Cutaneous lupus and cytokines 
Cutaneous lupus erythematosus represents an autoimmune disease characterized by 
photosensitivity, apoptosis of keratinocytes and an inflammatory infiltrate in superficial 
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and/or deep compartments of the skin. Skin disease is the second most common 
manifestation in SLE patients. Although clearly there is a link between the skin and systemic 
manifestations of SLE, often the skin may flare independently or patients may have SLE 
without skin disease. Treatments also may improve the skin, systemic disease, or both, 
suggesting that there are differences pathogenetically between skin and systemic findings in 
cutaneous lupus.  
UV-irradiation is a well-known trigger of apoptosis in keratinocytes and there is 
accumulating evidence that abnormalities in the generation and clearance of apoptotic 
material is an important source of antigens in autoimmune diseases (Caricchio et al 2003). 
Phototesting studies suggest that both UVB and UVA are potentially pathogenic  
wavelengths, although it is clear that UVA induction requires higher doses of light relative 
to UVB. UV light can  induce the binding of autoantibodies  to selected nuclear antigens 
located on blebs or apoptotic bodies of skin. It has been suggested that these bleb-associated 
antigens may then be phagocyted, packaged, and presented to lymphocytes, thereby 
stimulating autoimmune responses (Casciola-Rosen  & Rosen   1997). The high presence of 
anti-Ro antibodies in cutaneous involvement in lupus might be explained because anti-Ro 
antibodies might interfere with protection from UV damage as genetic knock-out of 60kD 
Ro resulted in an SLE-like illness in multiple strains of mice that were susceptible to UV 
damage (Xue et al 2003).  
Exposure of keratinocytes to UVB results in the synthesis of many pro-inflammatory 
cytokines, including tumor necrosis factor-a (TNF-ǂ) interleukin-1ǂ (IL-1ǂ), IL-6, IL-8, and 
IL-10 (Brink et al 2000). TNF-ǂ is not only involved in the mediation of local inflammatory 
reactions within the epidermis, but may also enter the circulation and cause systemic effects. 
There is an association of subacute cutaneous LE  with the extended HLA haplotype   
DRB1*03-B*08. Contained within this haplotype is the TNF2 allele, a TNFǂ promoter 
polymorphism, associated with increased TNFǂ production (Werth et al 2000). 
UV induced injury trigger  the initial chemokine  production and release results in a first wave 
of skin-homing memory T cells and plasmacytoid dendritic cells (PDCs) via chemokine driven 
pathways. DNA, RNA, and immune complexes, present in skin containing apoptotic material, 
can serve as IFN-alpha inducers  in PDCs . There is a higher frequency of PDCs in skin 
compared to the blood of patients with SLE, suggesting that PDCs migrate from the circulation 
into the skin. Under normal conditions PDCs are not able to respond to self nucleic acids,  but 
in lupus PDCs became activated to produce INF-ǂ by self nucleic acids in complex with 
autoantibodies to DNA or nucleoproteins. These immuno-complexes trigger innate activation 
of PDC through TLR7 and 9 and lead to sustained production of INF-ǂ (show Figure 2) that 
may induce  an unabated maturation of dendritic cells  and the activation of autoreactive  T 
cells.    Enhanced type I IFN signaling promotes Th1-biased inflammation in cutaneous lupus. 
IFN-ǂ can amplify cutaneous inflammation via the induction of chemokines that recruit  
potentially auto-reactive T cells into the skin. For example, IFN-ǂ induces the production of 
chemokines, CXCL9, CXCL10, and CXCL11, which recruit chemokine receptor CXCR3 
expressing lymphocytes, including Th1 cells and CD8+ T cells, from peripheral blood into 
inflamed skin (Wenzel et al 2005). Large numbers of CXCR3+ lymphocytes are detected  in 
cutaneous lupus skin lesions. The majority of these infiltrating cells are memory T CD4+ 
lymphocytes. Among memory T cell subsets, CXCR3 is predominantly expressed on the 
surface of IFN-Ǆ-producing Th1 cells, generating a proinflammatory effector response (Meller 
et al 2005). Hence, UV-irradiation may induce chemokine production and release, 
subsequently recruiting a first wave of skin-homing memory T cells and PDCs to sites of UV-
injury which produce cytokine-mediated inflammation and tissue damage. 
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4.2 Neuropsychiatric SLE 
Neuropsychiatric systemic lupus erythematosus (NPSLE) involves neurological 
manifestations seen in the central, peripheral, and autonomic nervous systems as well as 
psychiatric disorders in patients with SLE in which other causes have been excluded. 
NPSLE may occur at any time during the course of the disease, and symptoms are extremely 
diverse, ranging from depression, psychosis, and seizures to stroke (Committee on 
Neuropsychiatric Lupus Nomenclature 1999).  Though the pathophysiology of NPSLE has 
not yet been elucidated, two mechanisms of damage, specifically those produced by 
autoantibodies, and inflammatory mediators, are implicated in NPSLE. The most common 
neuropathologic features are multifocal microinfarcts  many of them due to the effect of 
anti-cardiolipin antibodies (Hanlyet al 1992).  
Cytokines and chemokines have  been implicated in the pathophysiology of NPSLE. Of the 
different cytokines studied, interleukin-6 (IL-6) has been shown to have the strongest 
positive association with NPSLE (Fragoso-Loyo et al 2007). IL-6 is a cytokine with high 
proinflammatory activity. IL-6 level in the CSF of NPSLE was reported to be elevated 
without damage of the blood-brain barrier, demonstrating an intrathecal synthesis of IL-6. 
In addition, the expression of IL-6 mRNA was elevated in the hippocampus and cerebral 
cortex, suggesting that IL-6 expression was increased within the entire CNS of NPSLE 
(Hirohata & Hayakawa 1999). Furthermore, when IL-6 activity was followed throughout 
symptom remission, they noted a decrease in CSF IL-6 activity measured indirectly, but not 
in serum IL-6 activity (Hirohata &  Miyamoto 1990). A recent study has shown that the 
sensitivity and specificity of CSF IL-6 for diagnosis of lupus psychosis was 87.5% and 92.3%, 
respectively, indicating that CSF IL-6 might be an effective marker for the diagnosis of lupus 
psychosis (Hirohata et al 2009). Although some cytokines are important biomarkers of 
NPSLE, the mechanism for the elevated levels of cytokines is thus far unknown.  Immune 
complexes in SLE can stimulate IFN-α and there is strong evidence in humans and in mice 
that IFN-α can cause neuropsychiatric manifestations. It has recently described using a 
bioassay containing plasmacytoid dendritic cells,  that NPSLE CSF induced significantly 
higher IFN-α compared with CSF from patients with multiple sclerosis or other autoimmune 
disease controls.  NPSLE CSF was 800-fold more potent at inducing IFN-α compared with 
paired serum, due to inhibitors present in serum (Santer et al 2009). Further immunological 
studies are expected to show how autoantibodies in SLE patients work to promote the 
cytokine storm associated with the pathophysiology of NPSLE. 
4.3 Cytokines role in lupus nephropathy 
Renal involvement in SLE  is present in over 50% of patient with active SLE and remains a 
major cause of end-stage renal disease and it is associated with a greater than four-fold 
increase in mortality in recent series (Bernatsky  et al., 2006; Boumpas et al., 1995). The 
pathologic manifestations of lupus nephritis (LN) are extremely diverse and may affect any 
or all renal compartments. The complexity of renal manifestations can be most easily 
approached using the World Health Organization Classification revised and updated in 
2004 (Weening  et al., 2004). 
The picture of cytokines present in LN is already complex and no single-cell population or 
cytokine has been decisively identified as a key mediator. Elevated circulating levels and/or 
tissue mRNA transcripts for several cytokines are reported in lupus patients and mice. On 
the other hand, the data regarding the relative importance of Th1-type versus Th2-type 
cytokines are inconsistent (Foster, 2005; Theofilopoulos et al., 2001).  
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The development of laser-manipulated micro dissection (LMD) from clinical biopsy 
specimens, together with  messenger RNA (mRNA) expression analysis in the targeted 
glomeruli or specific regions of interest, using real-time quantitative PCR,  has allowed to 
explore the single-cell cytokine profile of the samples from the LN patients. Interestingly a 
recent study, using LMD and PCR analysis of renal biopsy samples from LN patients has 
showed a negative correlation between the level of IL-2 and renal damage while a positive 
correlation between IL-17 and renal damage was evidenced. Indicating that IL-2 and IL-17 
play opposite roles in SLE development, suggesting that IL-2 may play a role in protecting 
against SLE development, while IL-17 might have a reverse effect (Wang et al., 2010). On the 
other hand, recent studies have highlighted the potential importance of the Th17 immune 
response in renal inflammatory disease. These include the identification and 
characterization of IL-17-producing T cells in nephritic kidneys of mice and humans, as well 
as evidence for the contribution of IL-17 and the IL-23/Th17 axis to renal tissue injury in LN 
(Turner et al., 2010; Zhang et al., 2009). 
5. Conclusions 
This chapter has focused in the  new insights about the role of cytokine  in the pathogenesis 
of Systemic Lupus Erythematosus. The imbalance in the levels of cytokines and their 
receptors found in SLE is clearly crucial to the development of the pathology of the disease. 
The cytokines are actively involved in both favoring the production of auto-antibodies as 
generating inflammation in affected tissues. Interactions between the cytokine milieus are 
complex and the attenuation of one cytokine  would need to be approached  with caution, 
considering effects on the cytokine network as a whole. There are still many facets of 
immunopathology of SLE elicited by  cytokines to be elucidated. A more in-depth 
understanding of these cytokines may be of clinical significance in the context of devising 
biomarkers or therapeutic agents. Cytokine therapy, is highly probable that, in the future 
will take a relevant place in the therapeutic armamentarium of autoimmune disorders. 
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